Rubedo Life Sciences Announces Clinical Development Plans for Lead Candidate RLS-1496, a First-in-Class GPX4 Modulator Targeting Aging Cells and Surrounding Tissues
CEO Frederick Beddingfield, III, MD, PhD, FAAD, FACMS, Leads Discussion on Longevity Science and Potential $600 Billion Addressable Global Market Opportunity at the 12th Annual Dermatology Summit
Rubedo Life Sciences, a clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, announced its clinical development plans for its lead candidate RLS-1496 at the 12th Annual Dermatology Summit. RLS-1496 is a first-in-class GPX4 modulator that targets aging cells and surrounding tissues.
Clinical Development Plans
RLS-1496 is a potential first-in-class disease-altering GPX4 modulator that targets aging cells and surrounding tissues. Rubedo’s Chief Scientific Officer Marco Quarta, PhD, presented details regarding the Phase 1 clinical trial for RLS-1496, which will begin in Spring 2025 in the Netherlands, and the kickoff of the company’s Series B financing round.
Longevity Science and Market Opportunity
CEO Frederick Beddingfield, III, MD, PhD, FAAD, FACMS, led a discussion on longevity science and its potential $600 billion addressable global market opportunity. He moderated a panel that included other longevity science experts and investors. According to Dr. Beddingfield, "Today, more than 1 billion adults are over the age of 60 and this number is expected to increase to 2 billion by 2050. Innovations to address the biological processes causing age-related chronic conditions, including heart disease, dementia, cancer, obesity, and metabolic syndrome, are needed to enable people to not only fight disease but also to empower a vibrant healthspan."
Company Overview
Rubedo Life Sciences is a clinical-stage biotech developing a broad portfolio of innovative selective cellular rejuvenation medicines targeting aging cells that drive chronic age-related diseases. The company’s proprietary AI-driven ALEMBIC drug discovery platform is developing novel first-in-class small molecules to selectively target pathologic and senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic, and other chronic disorders.
Conclusion
Rubedo Life Sciences is at the forefront of the new era in longevity science, with a mission to help adults live longer and healthier lives. With its lead candidate RLS-1496 entering Phase 1 clinical trials in Spring 2025, the company is poised to make a significant impact in the field of longevity science.
FAQs
Q: What is Rubedo Life Sciences’ mission?
A: Rubedo Life Sciences is developing a broad portfolio of innovative selective cellular rejuvenation medicines targeting aging cells that drive chronic age-related diseases.
Q: What is RLS-1496?
A: RLS-1496 is a potential first-in-class disease-altering GPX4 modulator that targets aging cells and surrounding tissues.
Q: What is the potential market opportunity for longevity science?
A: According to Bank of America analysts, the longevity market has the potential to be a $600 billion addressable global market opportunity.
Q: When will RLS-1496 enter Phase 1 clinical trials?
A: RLS-1496 will enter Phase 1 clinical trials in Spring 2025 in the Netherlands.
